Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEI PHARMA, INC.

(MEIP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MEI Pharma Shares Rise 22% After Positive Data for Zandelisib Trial

11/30/2021 | 10:07am EST

By Chris Wack

MEI Pharma Inc. shares were up 22%, to $3, after it and Kyowa Kirin Co. said a Phase 2 study evaluating zandelisib as a single agent for follicular lymphoma patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate as determined by Independent Review Committee assessment in the primary efficacy population.

The companies also said 35.2% of patients achieved a complete response.

The data are currently insufficiently mature to accurately estimate duration of response. In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months, median duration of follow-up in the total study population, interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%.

Patients enrolled in the study will continue to be followed for safety and duration of response.

Zandelisib is an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

11-30-21 1007ET

Stocks mentioned in the article
ChangeLast1st jan.
KYOWA KIRIN CO. LTD. -0.31% 2916 Delayed Quote.-6.99%
MEI PHARMA, INC. -3.11% 2.18 Delayed Quote.-18.35%
All news about MEI PHARMA, INC.
01/10MEI PHARMA : January 2022 Corporate Presentation
PU
01/03MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
2021MEI PHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exh..
AQ
2021MEI PHARMA, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submis..
AQ
2021MEI PHARMA : Announces Pricing of Public Offering of Common Stock - Form 8-K
PU
2021MEI PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021MEI Pharma Closes Common Stock Offering
MT
2021MEI Pharma Announces Closing of Public Offering of Common Stock
BU
2021MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
2021MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Financials (USD)
Sales 2022 35,0 M - -
Net income 2022 -82,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,28x
Yield 2022 -
Capitalization 290 M 290 M -
Capi. / Sales 2022 8,28x
Capi. / Sales 2023 2,53x
Nbr of Employees 76
Free-Float 99,4%
Chart MEI PHARMA, INC.
Duration : Period :
MEI Pharma, Inc. Technical Analysis Chart | MEIP | US55279B2025 | MarketScreener
Technical analysis trends MEI PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 2,18 $
Average target price 10,89 $
Spread / Average Target 399%
EPS Revisions
Managers and Directors
Daniel P. Gold President, Chief Executive Officer & Director
Brian G. Drazba Chief Financial Officer & Secretary
Christine Anna White Non-Executive Chairman
Richard G. Ghalie Chief Medical Officer
David M. Urso Chief Operating Officer & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MEI PHARMA, INC.-18.35%290
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356